September 24-26, 2024 | Boston, MA

6th Annual

RAS-Targeted Drug Development Summit

Defeating the Holy Grail Target in Precision Oncology

38+ Field-Leading Speakers

150+ Biopharma & Academic KOL Attendees

3 Jam-Pack Days of RAS Insights

2 Tracks of Brand-New Content

Overcome Diverse Clinical Resistance Mechanisms with Emerging First- & Best-In-Class Combination & Monotherapies to Effectively Treat Patients with RAS-Driven Lung, Colorectal & Pancreatic Cancers

38+ World-Class Speakers, Including:

Emily Chan
Executive Medical Director, Oncology Global Development
Amgen

Reagan Jarvis
Chief Executive Officer
Anocca

Peter DeMuth
Chief Scientific Officer
Elicio Therapeutics

Kevin Webster
Chief Scientific Officer
Frontier Medicines

Qiang Lu
Co-Founder & Chairman
GenFleet Therapeutics

Geoff Oxnard
Vice President, Clinical Development, Global Head, Thoracic Cancer
Loxo@Lilly

Andreas Weiss
Associate Director, Oncology Drug Discovery
Novartis

Jan Smith
Chief Scientific Officer
Revolution Medicines

Ahmadur Rahman
Senior Clinical Director & Clinical Science Lead, Global Oncology Research & Development
Roche

Proud to Partner With: biodesix · TEMPUS · Genialis · CERTIS ONCOLOGY INTELLIGENCE® · REACTION BIOLOGY

+1 617 455 4188 | info@hansonwade.com | @Undruggable | RAS-Targeted Drug Discovery and Development | www.ras-drugdevelopment.com

hansonwade

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

WELCOME TO THE 6TH ANNUAL RAS-TARGETED DRUG DEVELOPMENT SUMMIT

To our global RAS community,

The race to target the remaining RAS mutants continues, with over 24 clinical and 70 pre-clinical stage programs stiving for first- and best-in-class. Now more than ever, we are witnessing this growing industry make strides to utilize novel modalities and elucidate mechanisms of resistance – **making treating patients with RAS mutant cancers beyond NSCLC, not just a possibility, but a reality**.

As the leading industry centered forum, the **6th RAS-Targeted Drug Development Summit 2024** returns to Boston dedicated to every aspect of discovery and development of RAS, from **discovery**, **though to clinical development**, to create effective frontline **RAS therapies for cancer for better patient outcomes**.

Over 3 days, 38+ leading stakeholders will exhibit breakthrough novel data, latest clinical advancements, proof-of-concept, and strategic perspectives. This year's summit will tackle some of the hottest advances and burning questions in the space such as:

- **Targeting more mutants with RAS(ON) form, pas-RAS approaches and non-canonical targets to combat cancers beyond NSCLC**
- **Defeating intrinsic or acquired mechanistic resistance and reducing off-target effects to ensure more effective RAS directed medicines reach the patient**
- **Showcasing vaccines, cell therapies, monovalent and heterobifunctional modalities with improved selective and potent to avoid cancer recurrence**
- **Investigating valuable combination approaches utilizing inhibitors of up and downstream high value targets such as SOS1, MEK, RAF and ERK**

Join 150+ of your biopharma and academic peers from **Early Discovery**, **Translational Oncology** and **Clinical Development** at the unrivalled end-to-end forum this September as we foster critical conversations and navigate the cutting-edge treatments- **empowering the developers of RAS-targeted therapies to make a positive impact on the future of cancer treatment**.

With this shared aspiration in mind, I eagerly anticipate your arrival to Boston this September as we continue to unlock the holy grail of precision oncology.

Kerry Holtham
Program Director - Small Molecules Series
Hanson Wade

NEW & NOTEWORTHY SESSIONS FOR 2024:

Taking a Direct Approach: FMC-376, a Direct Inhibitor of ON+OFF KRAS G12C, Overcomes the Primary Drivers of Both Innate & Acquired Resistance
Kevin Webster, Chief Scientific Officer, **Frontier Medicines**

Inhibiting Phosphocreatine Dependent Energetic Pathway in RAS-Driven Colorectal Cancer by Blocking the SLC6A8 Creatine Transporter by Ompenaclib
Isabel Kurth, Senior Vice President, Research, **Inspirna**

Targeting Beyond G12C in RAS-Addicted Cancers: Opportunities Using RAS(ON) Tri-Complex Inhibitors
Jan Smith, Chief Scientific Officer, **Revolution Medicines**

Fulzerasib – A Journey from Second Line to First Line
Yu Wang, Chief Medical Officer, **GenFleet Therapeutics**

Asking More of Small Molecule KRAS Inhibition: Combination with Immunotherapy & Beyond G12C
Geoff Oxnard, Vice President, Clinical Development Global Head, Thoracic Cancer, **Loxo@Lilly**

WHAT IS NEW FOR 2024:

38+ Expert Speakers on the Frontline of RAS-Targeting

40% Brand New Companies Joining the Speaker Faculty

9+ Hours of Dedicated Networking

6 Revamped Interactive Workshops

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

New Companies on the 2024 Agenda

GENFLEET THERAPEUTICS
HOOKIPA PHARMA
Biomed Valley Discoveries
Inspirna
NIH NATIONAL CANCER INSTITUTE
PHusis Therapeutics
RANOK Therapeutics
RYVU THERAPEUTICS
Thryv THERAPEUTICS
vividion THERAPEUTICS
zentalis
IPSEN Innovation for patient care
BOUNDLESS BIO

BE HEARD BY SHOWCASING YOUR SCIENTIFIC POSTER

- Contribute to the conversation and share your cutting-edge research
- Network with your fellow oncogenic RAS-targeting community to communicate your breakthrough discoveries
- Forge new collaborations that will shape your RAS-targeted programs

Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

2024 AGENDA HIGHLIGHTS

6th Annual RAS-Targeted Drug Development Summit

September 24-26, 2024 | Boston, MA

PRE-CONFERENCE WORKSHOP DAY

- Explore the **systems biology** & pharmacology tools powering the deconvolution of RAS regulatory networks and debunk safety concerns of targeting **wild type KRAS**
- Interrogate mechanisms of action and **navigate agent synergy** in the pre-clinic and clinic to define the optimal combination therapy in NSCLC and beyond
- Leveraging genomic and biomarker data to predict clinical trial outcomes by **tackle acquired resistance** and improving patient response rates

PLENARY SESSIONS

- Witness the surge in innovative strides from Amgen, GenFleet Therapeutics, Novartis and Frontier Medicines to **discover, validate** and **translate pan-RAS inhibitors** and make broad spectrum coverage of heterogenous mutation points a reality
- Cast your attention to the pioneering **vertical pathway targeting** programs, from RAF/MEK/ERK to PI3K, leading the way to address acquire resistance and avoid cancer recurrence
- Receive a comprehensive update and look to the future of the **approved monotherapies** targeting G12C and scout the evolving roadmap to **first-in-class compounds for CRC** and **PDAC**

TRACK A: DRUG DISCOVERY & PRE-CLINICAL DEVELOPMENT

- Discover the latest modalities paving the way for best-in-class, boasting improved depth and durability of response, with talks on novel RAS-targeting **PROTACs**, **molecular glues**, **cell therapies** and **vaccines**
- Explore the latest early discovery efforts that are exploiting novel mechanisms of actions and **non-canonical targets** for single agent or combination therapy, including the development of CHAMPs and ULK1/2 inhibitors of autophagy
- Join peers from the following departments and applications: **Early Discovery**, **Molecular** & **Cancer Biology**, **Cell Signaling** & **Medicinal Chemistry**

TRACK B: TRANSLATION & CLINICAL DEVELOPMENT

- Marvel at the latest developments in next-generation RAS-inhibitors as biopharma race to develop **G12C(ON)**, **G12D** and **G12V inhibitors** with improved potency and selectivity
- De-risk your progression from pre-clinic to clinical development as we explore the paradigm of advancing *in* and *ex vivo* models with improved predictive value
- Get updated on the latest clinical insights and learn how Roche and Loxo@Lilly are striving for the **next RAS approval** in NSCLC
- Join peers from the following departments and applications: **Translational Medicine**, **Clinical Operations**, **Medical Affairs** & **Commercialization**

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

HEAR FROM PIONEERING COMPANIES TARGETING THE ENTIRE RAS PATHWAY

6th Annual RAS-Targeted Drug Development Summit



SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

Meet the 2024 Expert Speaker Faculty

6th Annual RAS-Targeted Drug Development Summit

September 24-26, 2024 | Boston, MA

Emily Chan
Executive Medical Director, Oncology Global Development
Amgen

Ryan Wurz
Scientific Associate Director
Amgen

Reagan Jarvis
Chief Executive Officer
Anocca

Chinatsu Sakata-Sakurai
Vice President, Primary Focus Lead, Targeted Protein Degradation
Astellas Pharma

Wolfgang Schwede
Principal Scientist
Bayer

Andrew Norris
Co-Founder & Chief Scientific Officer
BCN Biosciences

Matthew Pink
Vice President, Business Development
Biodesix

Brent Kreider
President
BioMed Valley Discoveries

Bobby Norgard
Senior Scientist, *In Vivo* Pharmacology
Boehringer Ingelheim Pharmaceuticals



Sudhir Chowdhry
Associate Director, Biology
Boundless Bio

Michael Boice
Senior Director, Scientific Engagement & Key Accounts
Certis Oncology

Biagio Ricciuti
Thoracic Medical Oncologist, Senior Scientist
Dana-Farber Cancer Institute

Zahra Kabiri
Assistant Professor
Duke University

Peter DeMuth
Chief Scientific Officer
Elicio Therapeutics

Kevin Webster
Chief Scientific Officer
Frontier Medicines

Qiang Lu
Co-founder & Chairman
GenFleet Therapeutics

Yu Wang
Chief Medical Officer
GenFleet Therapeutics

Rafael Rosengarten
Chief Executive Officer
Genialis

Joseph Mancias
Assistant Professor of Radiation Oncology
Harvard Medical School & Dana-Farber Cancer Institute

Rebecca Heist
Associate Professor of Medicine
Harvard Medical School
Thoracic Oncologist
Massachusetts General Hospital



Henning Lauterbach
Vice President, Immunology Research & Clinical Biomarkers
HOOKIPA Pharma

Isabel Kurth
Senior Vice President, Research
Inspirna

Christopher Hupp
Senior Director, External Innovation, Chemistry
Ipsen Bioscience

Andrea Wang-Gillam
Chief Medical Officer
Jacobio Pharmaceuticals

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

Meet the 2024 Expert Speaker Faculty

6th Annual RAS-Targeted Drug Development Summit

September 24-26, 2024 | Boston, MA

Hetika Vora Patel
Scientist, Translational Research
Kura Oncology

Geoff Oxnard
Vice President, Clinical Development Global Head, Thoracic Cancer
Loxo@Lilly

Ji Luo
Senior Investigator & Head, Oncogenic Signaling Section
National Cancer Institute

Bradley Quade
Senior Scientist, Structural Biology
Nested Therapeutics

Andreas Weiss
Associate Director, Oncology Drug Discovery
Novartis

Lynn Kirkpatrick
Chief Executive Officer
PHusis Therapeutics

Kevin Foley
Co-founder & Chief Scientific Officer
Ranok Therapeutics

Jan Smith
Chief Scientific Officer
Revolution Medicines

Ahmadur Rahman
Senior Clinical Director & Clinical Science Lead, Global Oncology Research & Development
Roche

Krzysztof Brzozka
Chief Scientific Officer & Executive Vice President
Ryvu Therapeutics

Sunanda Singh
Founder & Chief Executive Officer
Singh Biotechnology

Joshua SK Bell
Senior Director, Data Solutions
Tempus

Eric Campeau
Vice President Translational Research
Thryv Therapeutics

Lyndsey Linke
Chief Executive Officer & Co-Founder
SiVEC Biotechnologies

Chiara Ambrogio
Associate Professor of Molecular Biology
University of Torino

Jonathan Pachter
Chief Scientific Officer
Verastem Oncology

Silvia Coma
Senior Director, Translational & Preclinical Research
Verastem Oncology

Joseph Klebba
Associate Director
Vividion Therapeutics

Nathan Jameson
Senior Scientist
Zentalis Pharmaceuticals

Gary Piazza
Chief Scientist
ADT Pharmaceuticals
& Professor, College Pharmacy
Auburn University

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

AGENDA AT A GLANCE

6th Annual RAS-Targeted Drug Development Summit

September 24-26, 2024 | Boston, MA

Pre-Conference Workshop Day
Tuesday, September 24

Check-In & Light Breakfast

Workshop A
Debunking Safety & Efficacy Concerns Surrounding **Targeting Wild Type KRAS** to Induce Tumur Regression

Workshop B
Exploring Optimal **Combinations within Vertical & Parallel Pathways to Clinically** Target NSCLC & Beyond

Morning Networking Break

Workshop C
Leveraging **Systems Biology & Pharmacology** Tools to Elucidate RAS Regulatory Networks & Reveal New Therapeutic Targets

Workshop D
Overcoming Cancer Recurrence by **Addressing Acquired Resistances** & Improving Patient Response Rates

Lunch Break & Networking

Workshop E
Exploring Mechanisms of Action & Navigating Agent Synergy in the Pre-Clinic to **Improve the Efficacy of Combination Therapies**

Workshop F
Interrogating **Innovative Trial Designs** to Improve Patient Stratification & Streamline Clinical Development

End of Pre-Conference Workshop Day

Conference Day One
Wednesday, September 25

Check-In & Light Breakfast

Plenary
Making Strides in the **Development of PAN-RAS Inhibitors** to Overcome Mutational Heterogeneity & Drug Phenotypically Diverse Cancers

Morning Break & Speed Networking

Drug Discovery & Pre-Clinical Development	Translation & Clinical Development
Pioneering the **Development of Non-Small Molecules** with Improved Depth & Durability of Response	Striving for Best-in-Class by Elevating the Potency & Selectivity of **Next-Generation RAS Inhibitors**

Lunch Networking Break

Expanding the Treatable Patient Population by Overcoming Hurdles in **Drug Discovery Beyond G12C** Mutations	Developing Next-Generating **Inhibitors to Non-Canonical Targets** to Overcome Resistance

Afternoon Networking Break & Poster Session

Plenary
Exploring **Innovations in Vertical Pathway Targeting** to Comprehensively Suppress Tumorigenic Activity & Overcome Mechanistic Resistance

End of Conference Day One

Conference Day Two
Thursday, September 26

Check-In & Light Breakfast

Plenary
Examining **Precision Monotherapies Post-Approval:** Learnings from Approved Drugs to Charter the Course for Next-Generation RAS-Targeting

Morning Networking Break

Drug Discovery & Pre-Clinical Development	Translation & Clinical Development
Spearheading the Development of **PROTACs & Molecular Glues** to Overcome Acquired Resistance	**Showcasing Clinical Phase I-III Compounds** with Improved Patient Response Rates & Safety

Lunch Networking Break

Employing **Chemistry & Biology Insights** to Improve the Potency & Safety of RAS-Targeting Candidates	**Advancing Translational Models** to Convey Complex Tumor Microenvironments & Improve Physiological Relevance

Afternoon Networking Break

Plenary
The Future Outlook on RAS-Targeting: Expanding Beyond NSCLC & G12C to Improve the Standard-of-Care for Patients with Unmet Clinical Need

End of 6th Annual RAS-Targeted Drug Development Summit

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

PRE-CONFERENCE WORKSHOP DAY | TUESDAY SEPTEMBER 24

8.00 Check-In & Light Breakfast

Workshop A

8.30 Debunking Safety & Efficacy Concerns Surrounding Targeting Wild Type KRAS to Induce Tumor Regression

Wild type KRAS continues to present a huge challenge in selectively targeting mutant variants implicated in cancer due to its structural similarity and essential cellular functions. Debate surrounds the feasibility and safety of directly targeting wild type KRAS, with concerns over potential off-target effects. Despite advances in structural and functional studies, these findings are yet to translate into clinically viable therapies drawing an increasing need for thought leaders to debate the potential consequences and mitigations.

This workshop will discuss:

- Can we target wild type KRAS? If so, can we differentiate between active and inactive states?
- How can we minimize toxicity in RAS targeted therapies?
- How to develop robust pre-clinical models to assess the efficacy and safety of wild type KRAS-targeting agents
- How to combine wild type KRAS inhibitors with other therapeutic agents?

Chiara Ambrogio, Associate Professor of Molecular Biology, **University of Torino**

Gary Piazza, Chief Scientist, **ADT Pharmaceutical** & Professor, College Pharmacy, **Auburn University**

Workshop B

8.30 Exploring Optimal Combinations within Vertical & Parallel Pathways to Clinically Target NSCLC & Beyond

The validation and clinical progression of novel agents targeting critical nodes in vertical and parallel signaling pathways are crucial to address adaptive and acquired resistance. However, informing disease-specific combination regimens for NSCLC and other RAS pathway-driven nmalignancies is no easy feat, with challenges surrounding synergistic drug design, cancer histotypes, and diverse patient profiles. This workshop will review the latest developments in targeting the RAS/MAPK pathway, parallel signaling cascades, address concerns for treating diverse oncology landscapes, and provide a clinical update on synergistic agents to help de-risk future combination regimes.

This workshop will discuss:

- Novel agents/approaches to target critical nodes in the vertical RAS/MAPK pathway and parallel signaling pathways to address adaptive and acquired resistance
- Disease-specific approaches/concerns for targeting NSCLC and additional RAS pathway-driven tumor types
- Translation from pre-clinical to clinical studies and update on new clinical data

Jonathan Pachter, Chief Scientific Officer, **Verastem Oncology**

Silvia Coma, Senior Director, Translational & Preclinical Research, **Verastem Oncology**

10.30 Morning Networking Break | An opportunity to network, discuss and collaborate with like-minded leaders

Workshop C

11.30 Leveraging Systems Biology & Pharmacology Tools to Elucidate RAS Regulatory Networks & Reveal New Therapeutic Targets

Systems biology and pharmacology has increasingly become instrumental in dissecting complex RAS networks including vertical and parallel pathways. However the entire RAS interactome is yet to be elucidated leaving untapped opportunity to overcome acquired resistance, inform combination strategies and target previously undrugged mutations and isoforms. This workshop will explore the molecular biology, omics and pharmacology tools used to elucidate RAS pathways and non-canonical approaches to target the broader oncogenic RAS landscape.

This workshop will discuss:

- What do we know about RAS networks, and what further dissection of pathways and interaction networks is needed?
- What is the utility of implementing quantitative multiplexed proteomics and how does this elucidate the RAS interactome? How can these assays inform combination therapies?
- How to leverage genomics, molecular biology and pharmacology tools to elucidate non-canonical approaches to target oncogenic RAS?
- What is the scope targeting non-oncogene addiction?

Joseph Mancias, Assistant Professor of Radiation Oncology, **Harvard Medical School & Dana-Farber Cancer Institute**

Ji Luo, Senior Investigator & Head, Oncogenic Signaling Section, **National Cancer Institute**

Workshop D

11.30 Addressing Acquired Resistance by Predicting Clinical Trial Outcomes & Improving Patient Response Rates

Acquired resistance to mutant-selective RAS inhibitors, including approved and investigational KRAS G12C inhibitors, presents significant challenge. It is critical that we not only consider the efficacy of direct inhibitor targeting but debate how additional drugging of vertical pathways can be crucial to overcoming feedback mechanisms. As recent advances in the last six months have uncovered novel mechanisms of RAS inhibitor resistance, this workshop will deep-dive into how we can improve patient response rates with genomic and biomarker data.

This workshop will discuss:

- How to identify and characterize mechanisms underlying RAS acquired resistance
- How to predict clinical trial outcomes before the clinic considering tumor heterogeneity
- How to develop predictive biomarkers for identifying patients at risk of resistance
- How to optimize the dosing and scheduling of single or combination therapies to delay or overcome resistance

Biagio Ricciuti, Thoracic Medical Oncologist, Senior Scientist, **Dana-Farber Cancer Institute**

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

1.30 Lunch & Networking Break

Workshop E

2.30 Exploring Mechanisms of Action & Navigating Agent Synergy in the Pre-clinic to Improve the Efficacy of Combination Therapies

Current pre-clinical exploration in combination strategies for targeting RAS-driven tumors is underscored by selecting synergistic agents with complementary mechanisms to overcome acquired resistance. Amidst the emergence of diverse modalities, a deeper understanding of the interplay between targeted proteins and up/downstream pathways is crucial, alongside toxicity risks. This workshop will shed light on promising combinations in pre-clinical models, debate novel drug pairs and direct/indirect co-treatments. These insights will drive the optimization of combination regimens to advance personalized cancer treatment paradigms for patients with unmet need.

This workshop will discuss:

- How to effectively identify synergistic agents with complementary mechanisms of action?
- What current combinations are being tested and how have these preformed?
- How to mitigate toxicity risks associated with combination therapies?
- How to translate promising pre-clinical findings into clinically viable combination regimens?

Andrew Norris, Co-Founder & Chief Scientific Officer, **BCN Biosciences**

Gary Piazza, Chief Scientist, **ADT Pharmaceutical** & Professor, College Pharmacy, **Auburn University**

Workshop F

2.30 Interrogating Innovative Trial Designs to Improve Patient Stratification & Streamline Clinical Development

From adaptive and basket trials, to biomarker-driven approaches, innovative trial design offers promising avenues in precision oncology for RAS-driven cancers. Such enhanced trail designs require careful consideration to encompass tumor heterogeneity, resistance risks and optimal dosing strategies. With many nuances to consider, this workshop will review the recent advancements that have underscored tailored treatment approaches and question how we can improve patient stratification to pave the way for continued innovation of trial design.

This workshop will discuss:

- Where have innovative clinical trials been implemented for RAS targeting drugs? Have these been successful?
- How to balance innovation with regulatory rigor in trial design?
- How to optimize trial endpoints to capture both short-term response and long-term outcomes in the context of combination therapies?
- How to address challenges related to cross-trial comparisons

Emily Chan, Executive Medical Director, Oncology Global Development **Amgen**

Rebecca Heist, Associate Professor of Medicine, **Harvard Medical School** & Thoracic Oncologist, **Massachusetts General Hospital**

4.30 End of Pre-Conference Workshop Day

> "Resistance and non-responses are still a common occurrence in clinics and a continued understanding of how to treat KRAS mutant tumors is still needed. This meeting gathers all the KRAS leaders in the field to figure out how to continue to combat this ever-changing complex problem."
>
> **Boehringer Ingelheim Pharmaceuticals**

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

CONFERENCE DAY ONE | WEDNESDAY SEPTEMBER 25

7.30 **Check-In & Light Breakfast**

Andrea Wang-Gillam
Chief Medical Officer
Jacobio Pharmaceuticals

8.20 **Chair's Opening Remarks**

Making Strides in the Development of PAN-RAS Inhibitors to Overcome Mutational Heterogeneity & Drug Phenotypically Diverse Cancers

Ryan Wurz
Scientific Associate Director
Amgen

8.30 NEW DATA **Learning from Sotorasib: From Mutant-Selective Covalent Inhibitors to Reversible Pan-KRAS Inhibitors**

- How structural insights from KRAS G12C inhibitors guided the design of inhibitors of other oncogenic KRAS mutants
- Pharmacological profiling of pan-KRAS inhibitors and demonstrations of pre-clinical efficacy
- Insights on the tolerability of wild-type KRAS inhibition and the role of on- and off-state targeting

9.00 **Panel Discussion: Does Pan-RAS Hold the Future of Precision Medicine? Exploring Combination Potential & Targeting Novel Isoforms**

- What is the current scope and strides in developing pan-RAS inhibitors?
- What combination therapies should be deployed with pan-RAS and how can we inform this?
- What is the future of pan-RAS? Will it replace mutant-specific therapies?

Panel Moderator: Chiara Ambrogio
Associate Professor of Molecular Biology
University of Torino

Andreas Weiss
Associate Director, Oncology Drug Discovery
Novartis

Kevin Webster
Chief Scientific Officer
Frontier Medicines

Ryan Wurz
Scientific Associate Director
Amgen

Qiang Lu
Co-founder & Chairman
GenFleet Therapeutics

Lyndsey Linke
Chief Executive Officer & Co-founder
SiVEC Biotechnologies

9.45 **Advancing PAN-RAS Inhibitors: Tackling Mutational Heterogeneity in Diverse Cancers Using Cutting-Edge Modalities**

- Alternatives to small-molecule drugs for mutant KRAS targeting
- Rationale for bacteria-mediated intracellular delivery of single-domain antibodies (VHH) as a next-generation therapy
- Introducing SVC-KRAb: a first-in-class pan-KRAS-targeting therapeutic

Joshua SK Bell
Senior Director, Data Solutions
Tempus

10.15 **Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development**

- KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, reveal critical insights for targeted therapy development
- Tempus' multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients
- Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes

10.45 **Morning Break & Speed Networking**
Our speed networking is the ideal opportunity to get face-to-face time with many of the brightest minds working in the field and introduce yourself to the attendees that you would like to have more in-depth conversations with. Benchmark against industry leaders & establish meaningful business relationships to pursue for therest of the conference and beyond.

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

TRACK A: Drug Discovery & Pre-Clinical Development

Chair: Christopher Hupp, Senior Director, External Innovation, Chemistry, **Ipsen Bioscience**

Pioneering the Development of Non-Small Molecules as the Next Phenomenon in Precision Oncology with Improved Depth & Durability

11.45 Unveiling the Potential of RAS-Targeted Vaccines as a Durable & Versatile Immunotherapy Solution

- How to elicit robust immune responses against KRAS with vaccination formats?
- How to enhance the action of key immune cells and generate robust tumor-specific immune responses?
- What challenges need to be overcome to expand development of vaccines for more complex cancers?

Peter DeMuth, Chief Scientific Officer, **Elicio Therapeutics**

BEYOND LUNG

12.15 RAS Mutant Targeting TCR-T Development & Manufacturing

- Reviewing precision HLA-peptide target mapping from mutant RAS sequences
- Showcasing TCR discovery from healthy donors and potency/safety characterization
- Exploring gene-edited autologous TCR-T manufacturing

Reagan Jarvis, Chief Executive Officer, **Anocca**

12.45 Development of an Arenavirus-Based Immunotherapy for Treatment of KRAS Mutant Cancer

- Introducing HOOKIPA's arenavirus platform and showcasing promising results observed in a Phase 1/2 trial in 1L R/M HPV16+ HNSCC patients
- Presenting the non-clinical development package of HB-700, targeting the 5 most prevalent KRAS mutations in pancreatic, colorectal, and lung cancers
- Discussing the clinical development plan for HB-700

Henning Lauterbach, Vice President, Immunology Research & Clinical Biomarkers, **HOOKIPA Pharma**

Virtual Presentation

NEW DATA BEYOND LUNG

TRACK B: Translation & Clinical Development

Chair: Eric Campeau, Vice President Translational Research, **Thryv Therapeutics**

Striving for Best-in-Class by Elevating the Potency & Selectivity of Next-Generation RAS Inhibitors

11.45 Taking a Direct Approach: FMC-376, a Direct Inhibitor of ON+OFF KRAS G12C, Overcomes the Primary Drivers of Both Innate & Acquired Resistance

- Discovery of FMC-376 and demonstration of ON + OFF dual acting MOA
- Demonstration of broad activity across PDX models representing diverse clinical resistance mechanisms
- Demonstration of CNS activity and combination efficacy

Kevin Webster, Chief Scientific Officer, **Frontier Medicines**

NEW DATA

12.15 Roundtable Discussion: Improving the Oral Bioavailability of RAS-Targeting Inhibitors to Maintain Coverage of the Target & Increase the Depth of Treatment

- Considering KRAS-driven tumors and biology, what is the significance of oral bioavailability for RAS-targeting inhibitors versus other administration routes?
- How to design and conduct pre-clinical studies to assess coverage of the target?

Eric Campeau, Vice President Translational Research, **Thryv Therapeutics**

12.45 Targeting Beyond G12C in RAS-Addicted Cancers: Opportunities Using RAS(ON) Tri-Complex Inhibitors

- Potential for RAS(ON) multi-selective inhibitors to treat RAS-addicted cancers
- Rationale for combination strategies using RAS(ON) inhibitor doublets and RAS(ON) inhibitors with standard-of-care therapies
- Pre-clinical evidence for combination benefits in the context of evolving clinical landscape

Jan Smith, Chief Scientific Officer, **Revolution Medicines**

1.15 Lunch & Networking Break

REGISTER NOW

Expanding the Treatable Patient Population by Overcoming Hurdles in Drug Discovery Beyond G12C Mutations

2.15 Addressing mKRAS Inhibitor Resistance with Hetero-Bifunctional mKRAS-HSP90 CHAMPs

- Resistance to mKRAS inhibitors involves a wide variety of mechanisms, including upregulation of receptor tyrosine kinase (RTK) signaling
- Developing chaperone-mediated, hetero-bifunctional small molecule agents (CHAMPs) that simultaneously target both mKRAS and HSP90, an RTK-regulating chaperone protein
- CHAMPs also have improved safety margins due to preferential drug accumulation in tumor tissues

Kevin Foley, Co-founder & Chief Scientific Officer, **Ranok Therapeutics**

NEW DATA

2.45 Designing Novel Pan-mut-KRAS Inhibitors

- Novel approach to targeting mut-KRAS without affecting wild type K-RAS
- Pleckstrin homology (PH) domains inhibitors selectively block the membrane localization of mutant KRAS, allowing opportunity for structural modelling of inhibitors
- Identification of clinical lead small molecule pan mut-KRAS inhibitors

Lynn Kirkpatrick, Chief Executive Officer, **PHusis Therapeutics**

3.15 Genialis(TM) krasID: a First-in-Class Biomarker to Predict Response & Benefit of KRAS Inhibitors

- Genialis krasID is the first biomarker of its kind, using RNAseq and machine learning to capture a complete picture of a tumor's vulnerability to KRAS inhibition
- The biomarker accurately predicts response and stratifies benefit in real world patient data, showing high concordance with published clinical trial results
- The biomarker is designed to perform across the spectrum of KRASi mechanisms, mutations and histologies

Rafael Rosengarten, Chief Executive Officer, **Genialis**

Developing Next-Generating Inhibitors to Non-Canonical Targets to Overcome Resistance

2.15 KO-2806, a Farnesyl transferase Inhibitor, Re-sensitizes KRASG12C NSCLC Tumors to KRASG12C Mutant-Specific Inhibitors

- Presenting the application of KO-2806 to overcome adaptive resistance to KRAS inhibitors, even in KRAS inhibitor pre-treated setting
- Elucidating how KO-2806 overcomes resistance (blockage of compensatory mTOR signaling, through inhibition of RHEB farnesylation)
- Showcasing the potential of KO-2806 to be a partner drug to overcome resistance to KRAS targeted monotherapies

Hetika Vora Patel, Scientist, Translational Research, **Kura Oncology**

NEW DATA

2.45 Nano-Antibody (SBT-100) Inhibits KRAS and STAT3, & Penetrates the Blood-Brain-Barrier

- Demonstrating SBT-100 binds and inhibits KRAS, its mutants, and STAT3
- Showcasing how SBT-100 rapidly penetrates the blood-brain-barrier
- Presenting how SBT-100 suppresses G12D & G13D tumors *in vivo*

Sunanda Singh, Founder & Chief Executive Officer, **Singh Biotechnology**

BEYOND LUNG NEW DATA

3.15 Panel Discussion: Exploring Model Types with Improved Predictive Value for RAS-Driven Tumors: Advantages, Challenges & Clinical Translation

- What are the most appropriate model types to recapitulate RAS-driven tumor biology accurately?
- How have different models currently be implemented in RAS pipelines?
- How to address the limitations of *in vitro* models in capturing the complexity of the tumor microenvironment
- How to standardize experimental endpoints across different model systems?

Panel Moderator: Ji Luo, Senior Investigator & Head, Oncogenic Signaling Section, **National Cancer Institute**

Zahra Kabiri, Assistant Professor, **Duke University**

Andrea Wang-Gillam, Chief Medical Officer, **Jacobio Pharmaceuticals**

3.45 Afternoon Break & Poster Session

As the research, discovery, and development into RAS-targeted therapies continues to progress from strength to strength, it is more important than ever to collaborate and learn with your peers, as we continue to advance these therapies to patients in need. Join our dedicated session to share your latest data and have the first look on what your peers are working on!

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

Exploring Innovations in Vertical Pathway Targeting to Comprehensively Suppress Tumorigenic Activity & Overcome Mechanistic Resistance

Brent Kreider
President
BioMed Valley Discoveries

BEYOND LUNG

4.15 **Ulixertinib, a Clinically Proven Safe & Effective ERK1/2 Inhibitor with Combination Therapy Potential for Overcoming Resistance via Reactivation of the MAPK Pathway**

- Safe and effective targeting of ERK1/2 in humans is possible with ulixertinib
- ERK inhibition provides the backbone for vertical combination treatment to overcome numerous MAPK reactivating resistance mechanisms
- ERK inhibition remains a critical option to be explored for patient benefit, both as first-line and to overcome RAS inhibitor resistance

Krzysztof Brzozka
Chief Scientific Officer &
Executive Vice President
Ryvu Therapeutics

BEYOND LUNG NEW DATA

4.45 **ONCO Prime – A Comprehensive Platform for Identification of KRAS-Specific Synthetic Lethal Targets Using Patient-Derived Cells**

- Showcasing Ryvu's cutting-edge drug discovery platform, uniquely combining high throughput capabilities with the precision and translational impact traditionally associated with later, lower throughput stages
- Leveraging human stem cell-derived model cells (PDC), patient-derived xenografts (PDXs) and clinical samples to create a groundbreaking approach to identify synthetic lethal (SL) targets specific to oncogenic pathways
- In conjunction with our novel ranking algorithm, these models have successfully identified potential drug targets in KRAS-mutant cells—targets that remained undetected in immortalized CRC cell lines, likely due to genetic and epigenetic alterations accumulated over years of cell culture

5.15 **Closing Remarks, End of Conference Day One & Drinks Reception**

"This conference is a great opportunity to exchange pioneering ideas and concepts with leaders in the RAS field and build collaborations, which hopefully results in improved treatment options for patients"

HOOKIPA Pharma

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

CONFERENCE DAY TWO | THURSDAY SEPTEMBER 26

8.00 **Check-In & Light Breakfast**

Andrea Wang-Gillam
Chief Medical Officer
Jacobio Pharmaceuticals

8.50 **Chair's Opening Remarks**

Examining Precision Monotherapies Post-Approval: Learnings from Approved Drugs to Charter the Course for Next-Generation RAS-Targeting

Emily Chan
Executive Medical Director, Oncology Global Development
Amgen

9.00 **Learnings from the RAS-Targeted Therapeutics Clinical Trials of Sotorasib**

- Showcasing where the approved KRAS inhibitors are today and how they get there
- Reviewing learnings from the sotorasib development journey
- Exploring what the future of monotherapies and combination regimes hold

Michael Boice
Senior Director, Scientific Engagement & Key Accounts
Certis Oncology

NEW DATA
BEYOND LUNG

9.30 **Overcoming Therapeutic Resistance & Efficacy Challenges in RAS-Mutant Cancers with Certis Oncology Intelligence®**

- Exploring CertisAI™ to predict the response of- and identify predictive biomarkers for- RAS-targeted therapies, including novel drug combinations and monotherapies
- Mimicking clinical scenarios, including prior treatment, radiotherapy, acquired drug resistance, metastases and immune response to evaluate resistance mechanisms and design novel strategies for RAS-driven lung, colorectal and pancreatic cancers
- Tracking tumor burden, response, and pathophysiological processes in clinically relevant cancer models, using advanced multi-modality imaging

Yu Wang
Chief Medical Officer
GenFleet Therapeutics

NEW DATA

9.45 **Fulzerasib – A Journey from Second Line to First Line**

- From Discovery to IND: Critical criteria to accelerate the pre-clinical development process
- Picking the best partner, at/for the right timing
- Key to survival: Differentiated global clinical development strategy and CMC

Matthew Pink
Vice President, Business Development
Biodesix

10.15 **Leveraging Multi-Omic Testing to Advance RAS-Targeted Cancer Therapies**

- Innovations in RAS Mutation Detection and Personalized Treatment: ddPCR™ testing enhances the detection of RAS mutations, facilitating earlier diagnosis, personalized therapy development, and longitudinal monitoring of disease recurrence in RAS-mutant cancers.
- Integrating Proteomics for Comprehensive RAS Targeting: Proteomic testing identifies a patients' immune response to RAS mutant positive cancers, enabling the identification of aggressive cancer phenotypes and informing combination strategies, such as enhanced surveillance, immunotherapy, and chemotherapy for improved patient outcomes.
- (Biodesix, Biodesix logo are registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.)

10.45 **Morning Networking Break**

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

TRACK A: Drug Discovery & Pre-Clinical Development

Chair: Christopher Hupp, Senior Director, External Innovation, Chemistry, **Ipsen Bioscience**

Spearheading the Development of RAS-Targeting PROTACs & Molecular Glues with Improved Selectivity to Overcome Acquired Resistance

11.45 Development of the Pan-RAF-MEK Molecular Glue NST-628 & Opportunities for RAF Paralog Selective Molecular Glues

- A rationale for developing a non-degrading RAF-MEK molecular glue in RAS-MAPK dependent cancers
- Design of NST-628, a pan-RAF-MEK molecular glue with best-in-class potential
- Opportunities for development of RAF paralog-selective induced stabilizers based on novel structural insights into RAF-MEK complexes

Bradley Quade, Senior Scientist, Structural Biology, **Nested Therapeutics**

BEYOND LUNG NEW DATA

12.15 Panel : Debating the Therapeutic Utility of PROTACs & Molecular Glues versus Direct Targeting of RAS to Strategize Best-in-Class Therapeutic Interventions

- What are the advantages of degrading versus direct targeting?
- How to monitor RAS turnover and the kinetics of degradation?
- What is the combination potential of monovalent and heterobifunctional small molecules?

Chair: Christopher Hupp, Senior Director, External Innovation, Chemistry, **Ipsen Bioscience**

Kevin Foley, Co-founder & Chief Scientific Officer, **Ranok Therapeutics**

Bradley Quade, Senior Scientist, Structural Biology, **Nested Therapeutics**

Chinatsu Sakata-Sakurai, Vice President, Primary Focus Lead, Targeted Protein Degradation, **Astellas Pharma**

TRACK B: Translation & Clinical Development

Chair: Eric Campeau, Vice President Translational Research, **Thryv Therapeutics**

Optimizing Therapeutic Dosing & Toxicity Management Across Clinical Phase I-III

11.45 Divarasib in NSCLC with a KRAS G12C Mutation

- Showcasing pre-clinical divarasib data
- Reviewing the clinical activity of divarasib in patients with NSCLC
- A look to the future: next steps in the development of divarasib in NSCLC

Ahmadur Rahman, Senior Clinical Director & Clinical Science Lead, Global Oncology Research & Development, **Roche**

12.15 Asking More of Small Molecule KRAS Inhibition: Combination with Immunotherapy & Beyond G12C

- Overall prognosis remains poor for KRAS mutant patients
- Olomorasib is a potent 2nd generation G12C inhibitor with early combination efficacy data suggesting olomorasib may be suited for 1L combinations with standard of care immunotherapy regimens in advanced NSCLC
- Borrowing from the discovery learnings from olomorasib, a highly mutant-selective G12D inhibitor and an isoform selective Pan-KRAS inhibitor are emerging from discovery

Geoff Oxnard, Vice President, Clinical Development Global Head, Thoracic Cancer, **Loxo@Lilly**

12.45 Lunch & Networking Break

REGISTER NOW

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

Employing Chemistry & Biology Insights to Improve the Potency & Safety of RAS-Targeting Candidates

1.45 Panel : Debating Optimal PK/PD Profiles to Carve Out the Optimal Inhibitor for Targeting RAS

- What are the advantages of covalent versus reversible binding from a safety and efficacy context?
- How to balance chemical modifications to improve drug-like properties such as solubility, bioavailability, and metabolic stability?
- How to optimize pharmacokinetic properties and minimize the risk of adverse drug reactions?

Panel Moderator: Andrew Norris, Co-Founder & Chief Scientific Officer, **BCN Biosciences**

Wolfgang Schwede, Principal Scientist, **Bayer**

Christopher Hupp, Senior Director, External Innovation, Chemistry, **Ipsen Bioscience**

2.30 Intercepting Resistance Gene Amplifications in MAPK Pathway-Activated Cancers

- RNR is a rate-limiting enzyme responsible for cellular de novo synthesis of dNTPs and is essential to the assembly and repair of ecDNA
- BBI-825 is a first-in-class, oral, and selective RNR inhibitor that has been shown to deplete deoxynucleotides (dNTPs) prevent acquired resistance mediated gene amplifications and ecDNA formation leading to anti-tumor efficacy in multiple MAPK driven pre-clinical models
- BBI-825 is currently being evaluated in the Phase 1/2 STARMAP clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761)

Sudhir Chowdhry, Associate Director, Biology, **Boundless Bio**

BEYOND LUNG NEW DATA

Advancing Translational Models to Convey Complex Tumor Microenvironments & Improve Physiological Relevance

1.45 *In Vivo* Modeling of Oncogenic KRAS Signaling Intensity to Elucidate Its Impact on Pancreatic Cancer Tumorigenesis

- The paradoxical impact of Codon-specific KRAS mutations on overall survival of PDAC patients at different stage of disease
- Developing and characterizing the first KRAS (Q61R) mouse model of pancreatic Cancer Generating four novel oncogenic KRAS signaling intensity mouse models to determine the role of KRAS signaling intensity in PDAC tumor development and find new vulnerabilities to different class of RAS inhibitors

BEYOND LUNG NEW DATA

Zahra Kabiri, Assistant Professor, **Duke University**

2.15 The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity With KRASG12C Inhibitors in Multiple KRASG12C Models

- Combination of Azenosertib, a novel, selective, WEE1 inhibitor, with KRAS G12C inhibitors demonstrates synergistic anticancer activity *in vitro* and *in vivo*
- The combination drives regression and extends duration of response in KRAS G12C mutant tumor models of NSCLC, CRC, and PDAC
- The combination overcomes innate and acquired resistance to KRAS G12C inhibition

Nathan Jameson, Senior Scientist, Translational Biology, **Zentalis Pharmaceuticals**

BEYOND LUNG NEW DATA

2.45 Reshaping the Tumor Microenvironment of KRAS G12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 & MEK Inhibition for Improved Immunotherapy Response

- How to use scRNAseq data as a blueprint to drive therapy regimens to prolong
- anti-tumor effects of KRAS cancer-targeted therapies
- Mechanistically, SOS1+MEK therapy revealed an increase in inflammatory cancer associated fibroblasts, macrophages, and decreased dendritic cell quality that results in an immunosuppressive microenvironment that can be leveraged therapeutically
- KRAS inhibition affects myeloid cell maturation and highlights the need for combining KRAS cancer-targeted therapy with myeloid activation to enhance anti-tumor effects

Bobby Norgard, Senior Scientist, In Vivo Pharmacology, **Boehringer Ingelheim Pharmaceuticals**

BEYOND LUNG

3.15 Afternoon Networking Break

REGISTER NOW

The Future Outlook on RAS-Targeting: Expanding Beyond NSCLC & G12C to Improve the Standard-of-Care for Patients with Unmet Clinical Need

Isabel Kurth
Senior Vice President, Research
Inspirna

BEYOND LUNG

3.45 Inhibiting Phosphocreatine Dependent Energetic Pathway in RAS-Driven Colorectal Cancer by Blocking the SLC6A8 Creatine Transporter by Ompenaclib

- CKB overexpression pathway in RAS mutated mCRC as a therapeutic target
- Ompenaclib – an oral small molecule blocking SLC 6A8 transport of phosphocreatine
- Pre-clinical and clinical data of ompenaclib activity in RAS mutated mCRC

Joseph Klebba
Associate Director
Vividion Therapeutics

NEW DATA

4.15 Targeting the RAS-PI3Kα Interaction as an Efficacious & Tolerated Means of Inhibiting the PI3K/AKT Pathway in RAS-Diven Cancers

- Identification and functionalization of C242, unique to p110α, to disrupt RAS-driven activation of PI3Kα
- Pre-clinical models identify disruption of the RAS-PI3Kα interaction as an efficacious and well tolerated means of targeting the PI3K/AKT pathway
- Detailed mechanistic exploration identifies the PI3K/AKT pathway as critical signaling node that drives resistance to direct targeting of KRAS-G12C. In both CDX and PDX models, addition of VVD's RAS-PI3K disruptors to a KRAS-G12C inhibitor dosing schedule provide more profound and durable responses

4.45 Chairs Closing Remarks & End of 6th Annual RAS-Targeted Drug Development Summit

> "The RAS-Targeted Drug Development Summit is the premiere meeting bringing together academic and industry partners with the ultimate goal of identifying how to effectively deploy RAS-targeted therapies to the patients in desperate need of these therapies. This symposium will increase opportunities for networking and collaborations thereby enhancing our own research program on RAS-targeted therapies and lending our expertise to other researchers."
>
> **Dana-Farber Cancer Institute**

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

2024 PARTNERS

Expertise Partner

Biodesix is a pioneering leader in the field of diagnostic solutions. Our company specializes in end-to-end diagnostic services, with strengths in developing custom diagnostics, clinical sample testing, ddPCR™, and clinical proteomics. We are your dedicated partner and versatile diagnostic service provider with multi-omic technologies, a track record of successful collaboration with industry leaders, and an unwavering dedication to diagnostic innovation.

www.biodesix.com/biopharma-services

Expertise Partner

Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.

www.tempus.com

Innovation Partner

Genialis is the RNA biomarker company. We are creating a world where healthcare delivers the best possible outcomes for patients, their families and communities. Genialis develops and validates clinically actionable biomarkers informed by the world's most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

www.genialis.com

Innovation Partner

Certis Oncology is the only translational partner that combines the predictive power of artificial intelligence with advanced preclinical cancer models to evaluate efficacy and understand the complex mechanisms of action inherent to drugs that target RAS pathways. Whether you want to evaluate your RAS-targeted compound's effect on previously radiated tumors *in vitro*, test it against immunotherapy-resistant subtypes *in vivo*, or investigate tumor microenvironment activity in humanized orthotopic patient-derived xenograft (O-PDX) cancer models, we support your forward-thinking approach to better translational data.

www.certisoncology.com

Exhibition Partner

Reaction Biology is a global contract research organization (CRO) that supports preclinical drug discovery with broad capabilities including protein and peptide production, over 2,000 biochemical and cell-based assays, biophysical testing, safety and toxicology, in vivo pharmacology models, and immuno-oncology services. Reaction also provides Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) analytical and functional bioassays for testing potency, efficacy, and safety of large biological molecules.

www.reactionbiology.com

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

Partner With Us

Your Comprehensive, Industry-Dedicated Global Platform to Foster New & Existing Relationships within the Booming RAS-Targeting Community

Despite the approval of KRAS G12C monotherapies, the momentum to develop **first and best-in-class RAS-targeting therapies grows**, drawing in new and distinguished biopharma in the race to improve the standard-of-care for RAS-driven cancers. The 6th Annual RAS-Targeted Drug Development Summit serves as a central hub for leading experts committed to discovering, validating and clinically progressing inhibitors, **PROTACs**, **molecular glues**, **cell therapies** and **RAS-targeting vaccines** to improve patient outcomes.

Partner with the **6th RAS-Targeted Drug Development Summit** to empower and support drug developers in their quest to effectively drug RAS driven cancers with your expertise and solutions in:

- Assay Development
- Screening Capabilities
- Computational Platforms
- Cancer Models
- Diagnostics
- Pre-clinical & Clinical Services

Benefit from Market Intelligence: Hear how and where biopharma are searching for services and solutions to facilitate their efforts to **develop**, **validate** and **clinically progress** novel small molecules, cell therapies and vaccines and match how your business can provide premium services accordingly

Showcase Your World-Class Solutions: Benefit from pre- and post-conference exposure to our comprehensive RAS community and increase market share through unique branding formats. Also, differentiate your services from other solution providers to **leverage your business from competitors**

Forge New Commercial Collaborations: With an all-encompassing room full of drug developers and decision makers dedicated to targeting oncogenic RAS, meet prospective clients during structured networking breaks, bespoke meetings and more informal networking receptions

ENQUIRE TODAY

Jacob Roberts-Kendall
Commercial Manager
Telephone: +1 617 455 4188
sponsor@hansonwade.com

SENIORITY OF ATTENDEES*



- Chief, President & VP – 24%
- Director & Head – 26%
- Professor – 6%
- Manager – 6%
- Scientist – 20%
- Other – 18%

TYPES OF COMPANIES ATTENDING*



- Drug Developers
- Academia & Research Institutes
- Equipment & Service Providers

*Statistics taken from the 5th RAS-Targeted Drug Development Summit 2023

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW

Ready to Register?

3 Easy Ways To Book

www.ras-drugdevelopment.com/take-part/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

More Reasons To Attend

DISCOVER and leverage first-hand technical and strategic insights from leading biopharma organizations striving for first- and best-in-class RAS-targeting drugs and regimes to address unmet patient need

BUILD your understanding into the current challenges, strategies, and solutions to truly capitalize on the therapeutic benefit of next generation inhibitors and emerging modalities

ENGAGE with your community and 150+ peers from leading biopharma with in-person networking opportunities to build complementary collaborations and partnerships

Secure Your Place

6th Annual RAS-Targeted Drug Development Summit

September 24-26, 2024 | Boston, MA

DRUG DEVELOPERS*	Register and Pay by Friday September 23 **(Save up to $100)**	On The Door
Conference + Workshop Day	$4,097	$4,197
Conference Only	$2,899	$2,999

ACADEMIC & NOT-FOR-PROFIT**	Register and Pay by Friday September 23 **(Save up to $100)**	On The Door
Conference + Workshop Day	$3,497	$3,597
Conference Only	$2,499	$2,599

SERVICE & SOLUTION PROVIDERS	Register and Pay by Friday September 23 **(Save up to $100)**	On The Door
Conference + Workshop Day	$4,997	$5,097
Conference Only	$3,599	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website for full pricing options or Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5+ Attendees

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com

VENUE



Revere Hotel Boston Common
200 Stuart Street, Boston, MA 02116

For further information or assistance, please visit:
www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

SAVE $100 BY REGISTERING BEFORE SEPTEMBER 23

CONTENTS

REGISTER NOW